TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06301789

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Effect of adding Mg sulfate as an adjuvant to bupivacain in U/S guided QLB for postoperative analgesia in lower abdominal cancer surgeries
Description: Bilateral ultrasound-guided transmuscular (anterior) quadratus lumborum block will be performed Each patient will be placed in the lateral position. the transducer will be placed in a transverse orientation on the flank just cranial to the iliac crest, then slide posteriorly to obtain an image of the quadratus lumborum muscle.echogenic needle will be inserted in-plane with the ultrasound beam in a posterior-to-anterior direction through the quadratus lumborum muscle until the ventral fascia of the muscle penetrated. At this point, the needle directed toward the fascial plan between the quadratus lumborum and the Psoas muscle; the correct position of the needle tip will be confirmed by injecting 3 mL of saline to separate the fascial layers at the lateral aspect of the quadratus lumborum muscle. Thereafter, the needle will be advanced more posteriorly between the quadratus muscle and psoas major muscle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Effect of adding Mg sulfate as an adjuvant to bupivacain in U/S guided QLB for postoperative analgesia in lower abdominal cancer surgeries
Description: Bilateral ultrasound-guided transmuscular (anterior) quadratus lumborum block will be performed Each patient will be placed in the lateral position. the transducer will be placed in a transverse orientation on the flank just cranial to the iliac crest, then slide posteriorly to obtain an image of the quadratus lumborum muscle.echogenic needle will be inserted in-plane with the ultrasound beam in a posterior-to-anterior direction through the quadratus lumborum muscle until the ventral fascia of the muscle penetrated. At this point, the needle directed toward the fascial plan between the quadratus lumborum and the Psoas muscle; the correct position of the needle tip will be confirmed by injecting 3 mL of saline to separate the fascial layers at the lateral aspect of the quadratus lumborum muscle. Thereafter, the needle will be advanced more posteriorly between the quadratus muscle and psoas major muscle
Study: NCT05044429

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous Lidocaine
Description: Patient will receive intravenous lidocaine 1.0-1.5 mg/kg/hour for 48 hours post-operatively in addition to standard of care (patient-controlled analgesia (PCA) pump)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Transversus abdominis plane (TAP) block
Description: Subject will receive 0.2% Ropivacaine at 6-10ml/hour through transversus abdominis plane (TAP) block for up to five days post-operatively in addition to standard of care (patient-controlled analgesia (PCA) pump)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Quadratus Lumborum (QL) Block
Description: Subject will receive 0.2% Ropivacaine at 6-10ml/hour through quadratus lumborum (QL) block for up to five days post-operatively in addition to standard of care (patient-controlled analgesia (PCA) pump)
Study: NCT05074641

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Direct myofascial release treatment
Description: Myofascial Release will be applied with Forearm and/or ulnar border of the palm. Deep Pressure will be applied and glided medially towards the base of the neck and/ or towards the upper scapular region

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bowen therapy
Description: Thumb of the therapist will be placed on the top of the targeted muscle. The skin will be carried away gently from the spine without disturbing the muscle. The thumb was then hooked into the lateral aspect of the muscle to form a pressure on the muscle. Then the thumb will be flattened in the medial direction, when this happened the muscle would plop or respond in some way.
Study: NCT05430425

Intervention type: OTHER
Intervention: respiratory safety
Description: Which of the 3 lma selection methods is effective in ensuring respiratory safety?

Intervention type: OTHER
Intervention: respiratory safety
Description: Which of the 3 lma selection methods is effective in ensuring respiratory safety?

Intervention type: OTHER
Intervention: respiratory safety
Description: Which of the 3 lma selection methods is effective in ensuring respiratory safety?
Study: NCT06218615

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention (Video)
Description: Watch video

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Answer survey questions
Study: NCT06390657

Intervention type: OTHER
Intervention: Planning CT, MRI
Description: SBRT-PATHY and CARBON-PATHY planning is performed for study purposes only. Patients will be treated according to standard radiotherapy as per institutional policies.~The planning images (CT, MRI) will be anonymized and used for planning purposes only.

Intervention type: OTHER
Intervention: Planning CT, MRI
Description: SBRT-PATHY and CARBON-PATHY planning is performed for study purposes only. Patients will be treated according to standard radiotherapy as per institutional policies.~The planning images (CT, MRI) will be anonymized and used for planning purposes only.
Study: NCT05828459

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OT-A201
Description: OT-A201 IV infusion qw or q2w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OT-A201
Description: OT-A201 IV infusion qw or q2w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OT-A201
Description: OT-A201 IV infusion qw or q2w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OT-A201
Description: OT-A201 IV infusion qw or q2w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OT-A201
Description: OT-A201 IV infusion qw or q2w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMids
Description: Combination regimen for hematological malignancy Lenalidomide: 25 mg on Days 1 to 21 of each 28-day cycle; or Pomalidomide: 4 mg on Days 1 to 21 of each 28-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Combination regimen for solid tumor Bevacizumab: 10 mg/m² q2w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Combination regimen for solid tumor Paclitaxel: 175 mg/m² q3w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TBD Compound
Description: Combination regimen for hematological malignancy
Study: NCT06138652

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: App
Description: Participants completed games on an app and sessions with a mentor focused on alleviating anxiety over 8 weeks.
Study: NCT05690997

Intervention type: OTHER
Group type: OTHER
Intervention: Intensive treatment
Description: If the mean home SBP preceding clinic follow-up is \>130mmHg, BP lowering treatment will be stepped up, and if the mean SBP preceding clinic follow-up is \<120mmHg, BP lowering treatment will be stepped down, until the target SBP of 120-129mmHg is achieved, or symptoms of hypotension prevent treatment to be further intensified.

Intervention type: OTHER
Group type: OTHER
Intervention: Standard treatment
Description: If the mean home SBP preceding clinic follow-up is \>140mmHg, BP lowering treatment will be stepped up, and if the mean SBP preceding clinic follow-up is \<130mmHg, BP lowering will be stepped down, until the target SBP 130-140mmg is achieved or symptoms of hypotension prevent treatment being intensified.
Study: NCT04666545

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MuST AKT
Description: A behavioural intervention designed to help participants identify and communicate with their social network about living kidney donation.
Study: NCT04001010

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PPP011
Description: 1 capsule inhaled 3 times a day with a vaporizer device

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 capsule inhaled 3 times a day with a vaporizer device
Study: NCT05694858

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Lignocaine-loaded maltose microneedle array patch
Description: A biodegradable maltose microneedle array patch containing 12.5 mg lignocaine that will be applied on the participant's dorsal aspect of the hand for 30 minutes prior to intravenous cannulation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EMLA 5% patch
Description: EMLA 5% cream applied on the dorsum of the participant's hand which will be subsequently covered with PVA-PET adhesive for 30 minutes prior to intravenous cannulation
Study: NCT05889767

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise tests (VO2 max test and 45-minute exercise session at 65% VO2 max)
Description: All participants will complete two exercise sessions:~1. VO2 max test on a cycle ergometer~2. Moderate exercise session (45 minutes at 65% measured VO2 max)
Study: NCT04907214

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin 25 MG
Description: Oral empagliflozin daily
Study: NCT05889767

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise tests (VO2 max test and 45-minute exercise session at 65% VO2 max)
Description: All participants will complete two exercise sessions:~1. VO2 max test on a cycle ergometer~2. Moderate exercise session (45 minutes at 65% measured VO2 max)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise tests (VO2 max test and 45-minute exercise session at 65% VO2 max)
Description: All participants will complete two exercise sessions:~1. VO2 max test on a cycle ergometer~2. Moderate exercise session (45 minutes at 65% measured VO2 max)
Study: NCT04710719

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone Injection
Description: Post surgical injection at site of keloid with TAC for 3 injections

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone Injection and 5-fluorouracil injection
Description: Post surgical injection at site of keloid with TAC and 5FU for 3 injections
Study: NCT05539443

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive Clinic Management (ICM)
Description: An in-person clinic management based on the intervention tested among stroke patients in the Stenting and Aggressive Medical Management for Preventing Recurrent Stroke in Intracranial Stenosis (SAMMPRIS) trial

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive tailored telehealth management (ITTM)
Description: A remote-monitoring blood pressure (BP) management strategy incorporating individualized lifestyle coaching and care planning based on the HyperLink telehealth management trial
Study: NCT06119230

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Activity Counselling
Description: Participants will receive a one hour goal setting session with a physiotherapist where they will use the feedback forms to create activity goals for the upcoming week of collection.
Study: NCT05430165

Intervention type: OTHER
Intervention: Standard mHealth screening (triage) tool
Description: Standard mHealth triage tool administered to eligible trauma patients by phone at 2 weeks, 1 month, 3 months, and 6 months post-hospital discharge. The mHealth triage tool is a survey that includes a 7-item questionnaire to identify their need for follow-up care.~The need for follow-up care at any of the 4 follow-ups is defined as a flagged response to ≥1 question on the 7-item screening survey.
Study: NCT04801732

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mulligan thoracic Sustained Natural Apophyseal Glides
Description: Extension Thoracic Sustained Natural Apophyseal Glides :~Patient position: The patient sits astride the end of the table with hands placed behind the neck to protract the scapulae allowing access to the mid thoracic spine for the therapist's hand.~Therapist position: Therapist stands on their most efficient side for a centrally applied Sustained Natural Apophyseal Glides.~Therapist grasp: The therapist's mobilizing hand (ulnar border) will apply a cephalad glide in line with the facet joint plane of the involved spinal level and the other arm holds the thoracic wall above the level to be mobilized.~Traction is applied prior to glide, which is achieved by therapist knee extension~Repetitions: Three sets of ten repetitions will be done after a trial for the patient to be familial with the technique.~and traditional treatment.
Study: NCT06240481

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Test Regimen
Description: toothpaste \& mouthwash

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Test Regimen
Description: toothpaste \& mouthwash

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Control Regimen
Description: toothpaste

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Control Regimen
Description: toothpaste
Study: NCT04801732

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: traditional treatments
Description: includes: Ice pack and Pendulum exercise and shoulder range of motion (elevation, depression, flexion, abduction, rotations).Stretching exercise for internal rotators and posterior capsule.~Strengthening exercise will be isometric in nature include external shoulder rotators, internal rotators, biceps, deltoid, and scapular stabilizers (rhomboids, trapezius, serratus anterior, Latissimus Dorsi , and pectoralis major muscles).
Study: NCT06408701

Intervention type: BIOLOGICAL
Intervention: Blood sampling
Description: Blood will be taken in larger quantity
Study: NCT06387108

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: training course
Description: Two-hour online training course for educational professionals at schools on depression and mental health in children and adolescents (including symptoms, causes, comorbidity, prevention) and practical tips for everyday school life to reduce stress.
Study: NCT05358041

Intervention type: DEVICE
Intervention: Robotic Bronchoscopy
Description: Replace the Super-D EMN navigational platform with Ion Robotic bronchoscopy platform guided with shape sensing technology
Study: NCT04650087

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apixaban 2.5 MG
Description: Participants will take Apixaban 2.5 MG twice a day, once in the morning and once in the evening for 30 days. Participants will be contacted (electronic or telephone) 2 days after starting the study medication and will continue up to day 90 after starting study treatment. Followup will occur from the time of discharge through the 30 day study period with contacts at 2 days, 10 days, 20 days and 30 days after discharge. Two additional study contacts will take place 45 days and 90 days after discharge.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will take placebo twice a day, once in the morning and once in the evening for 30 days. Participants will be contacted (electronic or telephone) 2 days after starting the study medication and will continue up to day 90 after starting study treatment. Followup will occur from the time of discharge through the 30 day study period with contacts at 2 days, 10 days, 20 days and 30 days after discharge. Two additional study contacts will take place 45 days and 90 days after discharge.
Study: NCT04890405

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standardized FMT
Description: The group includes 35 patients. They will receive standardized FMT. Fecal bacteria capsules are used for fecal bacteria transplantation, 16 capsules are used each time, each capsule contains 200mg of fecal bacteria, and it is used orally. It was given only once.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Precision Flora Transplantation
Description: The group includes 35 patients. They will receive Precision Flora Transplantation. They were used self-developed precision transplant capsules for precision flora transplantation. 4 capsules are used each time. Each capsule contains 400mg of various probiotics effective against diarrhea. It is used orally, once a day,for 28 days.
Study: NCT05258422

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: stereotactic body radiotherapy, 20 Gy in 1 fraction
Description: A single dose of focused radiation therapy of 20 Gy in 1 fraction to the PTV of the arrhythmogenic substrate
Study: NCT00780728

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sildenafil
Study: NCT05383508

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CA35
Description: Nicotine concentration: 3.5 % e-liquid flavor: Tobacco

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CA35
Description: Nicotine concentration: 3.5 % e-liquid flavor: Tobacco

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CA35
Description: Nicotine concentration: 3.5 % e-liquid flavor: Tobacco

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CA35
Description: Nicotine concentration: 3.5 % e-liquid flavor: Tobacco

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CA35
Description: Nicotine concentration: 3.5 % e-liquid flavor: Tobacco

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CA35
Description: Nicotine concentration: 3.5 % e-liquid flavor: Tobacco

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CM35
Description: Nicotine concentration: 3.5 % e-liquid flavor: Menthol

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CM35
Description: Nicotine concentration: 3.5 % e-liquid flavor: Menthol

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CM35
Description: Nicotine concentration: 3.5 % e-liquid flavor: Menthol

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CM35
Description: Nicotine concentration: 3.5 % e-liquid flavor: Menthol

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CM35
Description: Nicotine concentration: 3.5 % e-liquid flavor: Menthol

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CM35
Description: Nicotine concentration: 3.5 % e-liquid flavor: Menthol

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cig
Description: Subjects' preferred brand of commercially available, regular or mentholated cigarettes

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cig
Description: Subjects' preferred brand of commercially available, regular or mentholated cigarettes

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cig
Description: Subjects' preferred brand of commercially available, regular or mentholated cigarettes

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cig
Description: Subjects' preferred brand of commercially available, regular or mentholated cigarettes

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cig
Description: Subjects' preferred brand of commercially available, regular or mentholated cigarettes

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cig
Description: Subjects' preferred brand of commercially available, regular or mentholated cigarettes
Study: NCT05230953

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA1273 vaccine
Description: fourth dose of the mRNA1273 vaccine (50 microgram) adminstered IM

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA1273 vaccine
Description: fourth dose of the mRNA1273 vaccine (50 microgram) adminstered IM
Study: NCT05524090

Intervention type: OTHER
Intervention: Implementation - International best-practice care
Description: The PREOPANC-4 project aims to safely implement the international standard of excellence for LAPC management and surgery using a multidisciplinary best-practice training program, based on the experiences of four leading international expert centers (i.e. NYU Langone Health, University of Colorado, Heidelberg University, and MD Anderson Cancer Center). We hypothesize that the PREOPANC-4 implementation project will result in the improvement in multidisciplinary patient management and selection in line with current international best-practice.
Study: NCT04891302

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clevudine
Description: Clevudine 150mg (5 capsules) once a day will be administered orally and can be taken regardless of food intake for 10 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo (5 capsules) once a day will be administered orally and can be taken regardless of food intake for 10 days
Study: NCT05268536

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: core stabilization exercise
Description: Patients will perform Plank, Bird dog, Double leg lifts, Prone cobra, Oblique twists exercises under the supervision of experienced Physiotherapist. All the participants will perform exercise for 6 weeks, 2 days a week for approximately 30-45 (including warm-up and cool-down).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: resistance exercise
Description: resistance exercise
Study: NCT05952726

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Expiratory cycling change at different levels of pressure support ventilation
Description: Four different levels of expiratory cycling will be randomly applied at 3 different degrees of pressure support.~Three end-inspiratory and three end-expiratory occlusion manoeuvres will be carried out at the end of 10 minute steps of ventilation during each set value expiratory cycling and pressure support level.~Total study time will be about 120 minutes. Levels of pressure support wil be clinical pressure support ± 4 cmH2O; expiratory cycling percentages applied for each pressure support step will be 15%, 30%, 45% and 60% of peak inspiratory flow.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Expiratory cycling change at different levels of pressure support ventilation
Description: Four different levels of expiratory cycling will be randomly applied at 3 different degrees of pressure support.~Three end-inspiratory and three end-expiratory occlusion manoeuvres will be carried out at the end of 10 minute steps of ventilation during each set value expiratory cycling and pressure support level.~Total study time will be about 120 minutes. Levels of pressure support wil be clinical pressure support ± 4 cmH2O; expiratory cycling percentages applied for each pressure support step will be 15%, 30%, 45% and 60% of peak inspiratory flow.
Study: NCT06165211

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nature sound listening
Description: The intervention group listened to nature sounds for 30 minutes during hemodialysis. Nature sounds consisting of bird, wind and tree sounds will be played.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Routine care
Description: Patients will watch the program they want on the bedside TV during hemodialysis.